---
layout: default
title: Pemetrexed
description: "Pemetrexed 的老藥新用潛力分析。模型預測等級 L5，包含 10 個預測適應症。查看 AI 預測與臨床證據完整報告。"
parent: 僅模型預測 (L5)
nav_order: 123
evidence_level: L1
indication_count: 10
---

# Pemetrexed

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
證據等級: <strong>L5</strong> | 預測適應症: <strong>10</strong> 個
</p>

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Pemetrexed 藥師筆記

## 一句話總結

<p class="key-answer" data-question="Pemetrexed 可以用於治療什麼新適應症？">
Pemetrexed 為多標靶抗葉酸類抗腫瘤藥物，TxGNN 預測其對惡性胸膜間皮瘤和腹膜間皮瘤有療效，此預測已獲多個 Phase III 臨床試驗證實，為該疾病的第一線標準治療。
</p>


---

## 快速總覽

| 項目 | 內容 |
|------|------|
| 藥品名稱 | Pemetrexed (培美曲塞) |
| DrugBank ID | DB00642 |
| 台灣商品名 | 愛寧達注射劑 (Alimta)、各廠學名藥 |
| 原適應症 | 非小細胞肺癌、惡性胸膜間皮瘤 |
| 預測新適應症 | malignant peritoneal mesothelioma、pleural adenomatoid tumor、pleural mesothelioma、pleural epithelioid mesothelioma、pleural sarcomatoid mesothelioma、pleural biphasic mesothelioma、pericardium cancer、well differentiated papillary mesothelioma、lymphohistiocytoid mesothelioma、malignant mesothelioma (disease) |
| 證據等級 | L1 (多個 RCT) |
| TxGNN 預測分數 | 0.9999+ |

---





## 預測適應症詳細分析

<details class="indication-section" open>
<summary>
<span class="indication-name">1. malignant peritoneal mesothelioma</span>
<span class="evidence-badge evidence-L2">L2</span>
<span class="prediction-score">99.99%</span> <span class="primary-badge">主要分析</span>
</summary>
<div class="indication-content">

<h3>為什麼這個預測合理？</h3>

<p>### 機轉連結</p>

<ol>
<li><strong>多標靶抗葉酸作用</strong>：Pemetrexed 抑制多個葉酸依賴性酵素 (DHFR、TS、GARFT)，阻斷嘌呤和嘧啶合成，對快速分裂的腫瘤細胞有效。</li>

<li><strong>間皮瘤共同病理</strong>：胸膜和腹膜間皮瘤均起源於間皮細胞，具有相似的分子特徵，對 pemetrexed 的反應機制相似。</li>

<li><strong>與鉑類藥物協同</strong>：Pemetrexed + cisplatin 的組合已證實對間皮瘤有效，此組合也適用於腹膜型。</li>
</ol>

<h3>臨床試驗</h3>

<table>
<thead>
<tr><th>試驗編號</th><th>階段</th><th>狀態</th><th>人數</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04462809" target="_blank">NCT04462809</a></td><td>PHASE2</td><td>UNKNOWN</td><td>40</td><td>A Three-Cohort Phase II Trial to Assess the Efficacy of a Maintenance Treatment ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02535312" target="_blank">NCT02535312</a></td><td>PHASE1, PHASE2</td><td>ACTIVE_NOT_RECRUITING</td><td>30</td><td>Phase I Study of TRC102 in Combination With Cisplatin and Pemetrexed in Patients...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00402766" target="_blank">NCT00402766</a></td><td>PHASE1</td><td>COMPLETED</td><td>19</td><td>Phase I Trial of Cisplatin, Pemetrexed, and Imatinib Mesylate in Unresectable or...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06543069" target="_blank">NCT06543069</a></td><td>PHASE2</td><td>RECRUITING</td><td>28</td><td>A Single-Arm, Phase II Clinical Study of Sintilimab and Bevacizumab Combined Wit...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05001880" target="_blank">NCT05001880</a></td><td>PHASE2</td><td>RECRUITING</td><td>66</td><td>Phase 2 Randomized Trial of Neoadjuvant or Palliative Chemotherapy With or Witho...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06057935" target="_blank">NCT06057935</a></td><td>PHASE2</td><td>RECRUITING</td><td>64</td><td>ICARuS II (Intraperitoneal Chemotherapy After cytoReductive Surgery): A Multicen...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01353482" target="_blank">NCT01353482</a></td><td>PHASE1, PHASE2</td><td>WITHDRAWN</td><td>0</td><td>A Phase I/II Study of First Line Vorinostat With Pemetrexed-cisplatin, in Patien...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00061477" target="_blank">NCT00061477</a></td><td>PHASE2</td><td>COMPLETED</td><td>48</td><td>ALIMTA Plus Gemcitabine as Front-Line Chemotherapy for Patients With Malignant P...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03875144" target="_blank">NCT03875144</a></td><td>PHASE2</td><td>SUSPENDED</td><td>66</td><td>Phase II Multicenter Randomized Trial Evaluating the Association of PIPAC and Sy...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03564691" target="_blank">NCT03564691</a></td><td>PHASE1</td><td>COMPLETED</td><td>470</td><td>A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-4830 as Monotherapy and...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02029690" target="_blank">NCT02029690</a></td><td>PHASE1</td><td>TERMINATED</td><td>85</td><td>Phase 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 Wi...</td></tr>
</tbody>
</table>

<h3>相關文獻</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/21160794/" target="_blank">21160794</a></td><td>2009</td><td>Article</td><td>World journal of gastrointesti</td><td>Malignant peritoneal mesothelioma.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/12057156/" target="_blank">12057156</a></td><td>2000</td><td>Article</td><td>Current treatment options in o</td><td>Peritoneal mesothelioma.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30450291/" target="_blank">30450291</a></td><td>2018</td><td>Article</td><td>Translational lung cancer rese</td><td>Malignant peritoneal mesothelioma: a review.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36765620/" target="_blank">36765620</a></td><td>2023</td><td>Article</td><td>Cancers</td><td>Diagnostic and Therapeutic Pathway in Diffuse Malignant Peritoneal Mesothelioma.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31287877/" target="_blank">31287877</a></td><td>2019</td><td>Article</td><td>Japanese journal of clinical o</td><td>Efficacy and safety of pemetrexed plus cisplatin as first-line chemotherapy in a...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/20047972/" target="_blank">20047972</a></td><td>2010</td><td>Article</td><td>British medical bulletin</td><td>Malignant mesothelioma.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/18841478/" target="_blank">18841478</a></td><td>2008</td><td>Article</td><td>Current treatment options in o</td><td>Peritoneal mesothelioma.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/23291819/" target="_blank">23291819</a></td><td>2013</td><td>Article</td><td>BMJ case reports</td><td>Malignant peritoneal mesothelioma (MPM) who responded to rechallenge with cispla...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36518655/" target="_blank">36518655</a></td><td>2022</td><td>Article</td><td>Journal of surgical case repor</td><td>Malignant peritoneal mesothelioma-a diagnostic challenge.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/35407498/" target="_blank">35407498</a></td><td>2022</td><td>Article</td><td>Journal of clinical medicine</td><td>Treatment of Patients with Malignant Peritoneal Mesothelioma.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/33257382/" target="_blank">33257382</a></td><td>2020</td><td>Article</td><td>BMJ case reports</td><td>Nivolumab for malignant peritoneal mesothelioma.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38142057/" target="_blank">38142057</a></td><td>2023</td><td>Article</td><td>BMJ case reports</td><td>Complete clinical remission of malignant peritoneal mesothelioma with systemic p...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/26941986/" target="_blank">26941986</a></td><td>2016</td><td>Article</td><td>Journal of gastrointestinal on</td><td>Diagnosis and management of patients with malignant peritoneal mesothelioma.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/29423664/" target="_blank">29423664</a></td><td>2018</td><td>Article</td><td>Annals of surgical oncology</td><td>Current Management and Future Opportunities for Peritoneal Metastases: Peritonea...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28594258/" target="_blank">28594258</a></td><td>2017</td><td>Article</td><td>Expert review of anticancer th</td><td>First-line chemotherapy with pemetrexed plus cisplatin for malignant peritoneal ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31583526/" target="_blank">31583526</a></td><td>2020</td><td>Article</td><td>Human cell</td><td>Establishment and characterization of a new malignant peritoneal mesothelioma ce...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31417959/" target="_blank">31417959</a></td><td>2019</td><td>Article</td><td>Pleura and peritoneum</td><td>Bidirectional chemotherapy allowing surgery and HIPEC for malignant peritoneal m...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38806763/" target="_blank">38806763</a></td><td>2024</td><td>Article</td><td>Annals of surgical oncology</td><td>Analysis of Treatment Strategies and Outcomes in Malignant Peritoneal Mesothelio...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/34723916/" target="_blank">34723916</a></td><td>2022</td><td>Article</td><td>Journal of immunotherapy (Hage</td><td>Treatment of Platinum Nonresponsive Metastatic Malignant Peritoneal Mesothelioma...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30834036/" target="_blank">30834036</a></td><td>2019</td><td>Article</td><td>Gastroenterology research</td><td>Malignant Peritoneal Mesothelioma Without Asbestos Exposure.</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. pleural adenomatoid tumor</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. pleural mesothelioma</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content">

<h3>臨床試驗（50 項）</h3>

<table>
<thead>
<tr><th>試驗編號</th><th>階段</th><th>狀態</th><th>人數</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00386815" target="_blank">NCT00386815</a></td><td>PHASE2</td><td>COMPLETED</td><td>20</td><td>Safety Confirmation Study of LY231514 Plus Cisplatin in Patients With Malignant ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03760575" target="_blank">NCT03760575</a></td><td>PHASE1</td><td>RECRUITING</td><td>20</td><td>Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Mali...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02303899" target="_blank">NCT02303899</a></td><td>PHASE2</td><td>COMPLETED</td><td>22</td><td>A Phase II Study of the Combination of Gemcitabine and Imatinib Mesylate in Peme...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06097728" target="_blank">NCT06097728</a></td><td>PHASE3</td><td>RECRUITING</td><td>825</td><td>A Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (M...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04153565" target="_blank">NCT04153565</a></td><td>PHASE1</td><td>COMPLETED</td><td>19</td><td>A Phase Ib Clinical Study to Evaluate the Safety and Efficacy of Pembrolizumab (...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00604461" target="_blank">NCT00604461</a></td><td>PHASE1, PHASE2</td><td>TERMINATED</td><td>13</td><td>Phase I/II Trial of Carboplatin, Bevacizumab and Pemetrexed in the First-Line Tr...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00996567" target="_blank">NCT00996567</a></td><td>PHASE2</td><td>COMPLETED</td><td>22</td><td>Phase II Study of Cetuximab Combined With Cisplatin or Carboplatin/Pemetrexed as...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02610140" target="_blank">NCT02610140</a></td><td>PHASE2</td><td>COMPLETED</td><td>248</td><td>A Randomized, Open-label, Active-controlled, Phase II Study of Intravenous Anetu...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05660616" target="_blank">NCT05660616</a></td><td>PHASE2</td><td>COMPLETED</td><td>40</td><td>Switch-Maintenance Gemcitabine After First-Line Chemotherapy (Pemetrexed-Platinu...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02899299" target="_blank">NCT02899299</a></td><td>PHASE3</td><td>COMPLETED</td><td>605</td><td>A Phase III, Randomized, Open Label Trial of Nivolumab in Combination With Ipili...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04334759" target="_blank">NCT04334759</a></td><td>PHASE3</td><td>COMPLETED</td><td>214</td><td>DREAM3R: DuRvalumab (MEDI4736) With chEmotherapy as First Line treAtment in Adva...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00969098" target="_blank">NCT00969098</a></td><td>N/A</td><td>UNKNOWN</td><td>150</td><td>Early Response Evaluation in Malignant Pleural Mesothelioma By Total Glycolytic ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00165503" target="_blank">NCT00165503</a></td><td>PHASE2</td><td>TERMINATED</td><td>16</td><td>A Phase II Feasibility Study of Pleurectomy/Decortication With Intraoperative In...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03489616" target="_blank">NCT03489616</a></td><td>NA</td><td>UNKNOWN</td><td>45</td><td>Chemotherapy Combination With Local Radiotherapy and rhGM-CSF for Oligometastati...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04462809" target="_blank">NCT04462809</a></td><td>PHASE2</td><td>UNKNOWN</td><td>40</td><td>A Three-Cohort Phase II Trial to Assess the Efficacy of a Maintenance Treatment ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00040625" target="_blank">NCT00040625</a></td><td>N/A</td><td>APPROVED_FOR_MARKETING</td><td>N/A</td><td>ALIMTA (Pemetrexed) Alone or in Combination With Cisplatin for Patients With Mal...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02535312" target="_blank">NCT02535312</a></td><td>PHASE1, PHASE2</td><td>ACTIVE_NOT_RECRUITING</td><td>30</td><td>Phase I Study of TRC102 in Combination With Cisplatin and Pemetrexed in Patients...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06416930" target="_blank">NCT06416930</a></td><td>PHASE2</td><td>NOT_YET_RECRUITING</td><td>59</td><td>Study of Cadonilimab Combined With Chemotherapy in Recurrent / Refractory Pleura...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01907100" target="_blank">NCT01907100</a></td><td>PHASE2, PHASE3</td><td>TERMINATED</td><td>545</td><td>LUME-Meso: Double Blind, Randomised, Multicentre, Phase II/III Study of Nintedan...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01675765" target="_blank">NCT01675765</a></td><td>PHASE1</td><td>COMPLETED</td><td>60</td><td>A Phase 1B Study to Evaluate the Safety and Induction of Immune Response of CRS-...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00407459" target="_blank">NCT00407459</a></td><td>PHASE2</td><td>COMPLETED</td><td>77</td><td>Phase II Study of the Combination of Bevacizumab Plus Pemetrexed and Carboplatin...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03920839" target="_blank">NCT03920839</a></td><td>PHASE1</td><td>WITHDRAWN</td><td>0</td><td>A Phase 1b Combination Study of INCMGA00012 Plus Chemotherapy in Participants Wi...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00402766" target="_blank">NCT00402766</a></td><td>PHASE1</td><td>COMPLETED</td><td>19</td><td>Phase I Trial of Cisplatin, Pemetrexed, and Imatinib Mesylate in Unresectable or...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06155279" target="_blank">NCT06155279</a></td><td>PHASE2</td><td>ACTIVE_NOT_RECRUITING</td><td>41</td><td>Phase II Study of Pembrolizumab in Combination With Cisplatin or Carboplatin and...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00867711" target="_blank">NCT00867711</a></td><td>N/A</td><td>COMPLETED</td><td>121</td><td>Pharmacogenetics of Pemetrexed and Carboplatin in Malignant Pleural Mesothelioma...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT07157956" target="_blank">NCT07157956</a></td><td>PHASE1, PHASE2</td><td>NOT_YET_RECRUITING</td><td>318</td><td>Phase I/II Clinical Study of CVL006 Combination Therapy in Advanced Solid Tumors</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00227630" target="_blank">NCT00227630</a></td><td>PHASE2</td><td>COMPLETED</td><td>59</td><td>A Phase II Feasibility Trial of Induction Chemotherapy Followed by Extrapleural ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02661659" target="_blank">NCT02661659</a></td><td>PHASE1</td><td>WITHDRAWN</td><td>0</td><td>A Phase Ib Trial of a Maintenance Multipeptide Vaccine (S-588210) in Patients Wi...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05930665" target="_blank">NCT05930665</a></td><td>PHASE2</td><td>RECRUITING</td><td>38</td><td>A Phase II, Prospective, Single Arm Trial of Cadonilimab in Combination With Bev...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00738582" target="_blank">NCT00738582</a></td><td>PHASE2</td><td>COMPLETED</td><td>89</td><td>An Open-Label Clinical Trial of MORAb-009 in Combination With Pemetrexed and Cis...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00651456" target="_blank">NCT00651456</a></td><td>PHASE2, PHASE3</td><td>COMPLETED</td><td>448</td><td>A Phase II-III Randomized Trial Pemetrexed-Cisplatin Chemotherapy With or Withou...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00281125" target="_blank">NCT00281125</a></td><td>PHASE1, PHASE2</td><td>TERMINATED</td><td>20</td><td>A Two-Cohort Phase I/II Trial of PTK787 and Pemetrexed With or Without Cisplatin...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02347917" target="_blank">NCT02347917</a></td><td>PHASE1, PHASE2</td><td>COMPLETED</td><td>28</td><td>A Phase I/II Clinical Study of BBI608 in Combination With Pemetrexed and Cisplat...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01064648" target="_blank">NCT01064648</a></td><td>PHASE1, PHASE2</td><td>ACTIVE_NOT_RECRUITING</td><td>117</td><td>A Phase I/Randomized Phase II Study of Cediranib (NSC#732208) Versus Placebo in ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT07121374" target="_blank">NCT07121374</a></td><td>PHASE1, PHASE2</td><td>RECRUITING</td><td>37</td><td>NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pl...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06875076" target="_blank">NCT06875076</a></td><td>PHASE2</td><td>RECRUITING</td><td>25</td><td>Efficacy and Safety of Ivonescimab (AK112) in Combination with Chemotherapy for ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03762018" target="_blank">NCT03762018</a></td><td>PHASE3</td><td>COMPLETED</td><td>401</td><td>A Multicentre Randomised Phase III Trial Comparing Atezolizumab Plus Bevacizumab...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02436733" target="_blank">NCT02436733</a></td><td>PHASE2</td><td>UNKNOWN</td><td>64</td><td>EORTC Randomized Phase II Study of Pleurectomy/ Decortication (P/D) Preceded or ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04843007" target="_blank">NCT04843007</a></td><td>N/A</td><td>COMPLETED</td><td>199</td><td>Alvopem® (Pemetrexed) Safety Assessment in Patients With Non-small Cell Lung Can...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01241682" target="_blank">NCT01241682</a></td><td>PHASE1</td><td>COMPLETED</td><td>10</td><td>Dendritic Cell-based Immunotherapy Combined With Low-dose Cyclophosphamide in Pa...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00541073" target="_blank">NCT00541073</a></td><td>PHASE2</td><td>COMPLETED</td><td>60</td><td>Phase 2 Pharmacological Study of Pemetrexed Administered With Cisplatin and a Vi...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01655225" target="_blank">NCT01655225</a></td><td>PHASE1</td><td>COMPLETED</td><td>156</td><td>A Phase 1 First-in-Human Dose Study of LY3023414 in Patients With Advanced Cance...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00251550" target="_blank">NCT00251550</a></td><td>PHASE1, PHASE2</td><td>COMPLETED</td><td>12</td><td>Phase I/II Study of LY231514 Plus Cisplatin in Patients With Malignant Pleural M...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04162015" target="_blank">NCT04162015</a></td><td>PHASE1</td><td>ACTIVE_NOT_RECRUITING</td><td>22</td><td>Feasibility and Safety of Neoadjuvant Nivolumab and Chemotherapy for Resectable ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05765084" target="_blank">NCT05765084</a></td><td>PHASE1, PHASE2</td><td>RECRUITING</td><td>15</td><td>Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Plat...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03715933" target="_blank">NCT03715933</a></td><td>PHASE1</td><td>RECRUITING</td><td>321</td><td>An Open-Label, Multicenter, First-in-Human, Phase 1 Dose-Escalation and Multicoh...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00942825" target="_blank">NCT00942825</a></td><td>PHASE2</td><td>COMPLETED</td><td>195</td><td>Phase II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin as F...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02707666" target="_blank">NCT02707666</a></td><td>PHASE1</td><td>TERMINATED</td><td>7</td><td>A Pilot Window-of-opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in P...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02899195" target="_blank">NCT02899195</a></td><td>PHASE2</td><td>COMPLETED</td><td>55</td><td>Open Label, Phase II Study of Anti - Programmed Death - Ligand 1 Antibody, Durva...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04158141" target="_blank">NCT04158141</a></td><td>PHASE3</td><td>TERMINATED</td><td>16</td><td>Phase III Randomized Trial of Pleurectomy/Decortication Plus Systemic Therapy Wi...</td></tr>
</tbody>
</table>

<h3>相關文獻（20 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37931632/" target="_blank">37931632</a></td><td>2023</td><td>Article</td><td>Lancet (London, England)</td><td>Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleura...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/12860938/" target="_blank">12860938</a></td><td>2003</td><td>Article</td><td>Journal of clinical oncology :</td><td>Phase III study of pemetrexed in combination with cisplatin versus cisplatin alo...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/34985934/" target="_blank">34985934</a></td><td>2022</td><td>Article</td><td>Journal of clinical oncology :</td><td>New Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/26719230/" target="_blank">26719230</a></td><td>2016</td><td>Article</td><td>Lancet (London, England)</td><td>Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/16807435/" target="_blank">16807435</a></td><td>2006</td><td>Article</td><td>Annals of oncology : official </td><td>Pemetrexed and malignant pleural mesothelioma.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37068376/" target="_blank">37068376</a></td><td>2023</td><td>Article</td><td>Journal of clinical oncology :</td><td>Flashback Foreword: Pemetrexed and Cisplatin in Mesothelioma.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/17181984/" target="_blank">17181984</a></td><td>2007</td><td>Article</td><td>Health technology assessment (</td><td>Pemetrexed disodium for the treatment of malignant pleural mesothelioma: a syste...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/34802094/" target="_blank">34802094</a></td><td>2022</td><td>Article</td><td>Drug delivery and translationa</td><td>EGFR-targeted pemetrexed therapy of malignant pleural mesothelioma.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36232554/" target="_blank">36232554</a></td><td>2022</td><td>Article</td><td>International journal of molec</td><td>Antagonist of Growth Hormone-Releasing Hormone Potentiates the Antitumor Effect ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/34750557/" target="_blank">34750557</a></td><td>2021</td><td>Article</td><td>Nature medicine</td><td>Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survi...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/29508763/" target="_blank">29508763</a></td><td>2018</td><td>Article</td><td>The Lancet. Oncology</td><td>Novel therapies for malignant pleural mesothelioma.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/32156681/" target="_blank">32156681</a></td><td>2020</td><td>Article</td><td>ESMO open</td><td>How I treat malignant pleural mesothelioma.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37661097/" target="_blank">37661097</a></td><td>2023</td><td>Article</td><td>Journal for immunotherapy of c</td><td>ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothe...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/35489694/" target="_blank">35489694</a></td><td>2022</td><td>Article</td><td>Journal of thoracic oncology :</td><td>BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Plati...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37975977/" target="_blank">37975977</a></td><td>2023</td><td>Article</td><td>Current treatment options in o</td><td>Updates in Management of Malignant Pleural Mesothelioma.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/12860935/" target="_blank">12860935</a></td><td>2003</td><td>Article</td><td>Journal of clinical oncology :</td><td>Pemetrexed and cisplatin for malignant pleural mesothelioma: a new standard of c...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31103412/" target="_blank">31103412</a></td><td>2019</td><td>Article</td><td>The Lancet. Respiratory medici</td><td>Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive p...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/34491782/" target="_blank">34491782</a></td><td>2022</td><td>Article</td><td>JCO oncology practice</td><td>Management of Advanced Pleural Mesothelioma-At the Crossroads.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28800871/" target="_blank">28800871</a></td><td>2017</td><td>Article</td><td>European journal of medicinal </td><td>Malignant Pleural Mesothelioma: State of the art and advanced cell therapy.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39818191/" target="_blank">39818191</a></td><td>2025</td><td>Article</td><td>Respiratory investigation</td><td>Current drug therapy for pleural mesothelioma.</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. pleural epithelioid mesothelioma</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content">

<h3>臨床試驗（13 項）</h3>

<table>
<thead>
<tr><th>試驗編號</th><th>階段</th><th>狀態</th><th>人數</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06097728" target="_blank">NCT06097728</a></td><td>PHASE3</td><td>RECRUITING</td><td>825</td><td>A Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (M...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06155279" target="_blank">NCT06155279</a></td><td>PHASE2</td><td>ACTIVE_NOT_RECRUITING</td><td>41</td><td>Phase II Study of Pembrolizumab in Combination With Cisplatin or Carboplatin and...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00227630" target="_blank">NCT00227630</a></td><td>PHASE2</td><td>COMPLETED</td><td>59</td><td>A Phase II Feasibility Trial of Induction Chemotherapy Followed by Extrapleural ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01064648" target="_blank">NCT01064648</a></td><td>PHASE1, PHASE2</td><td>ACTIVE_NOT_RECRUITING</td><td>117</td><td>A Phase I/Randomized Phase II Study of Cediranib (NSC#732208) Versus Placebo in ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT07121374" target="_blank">NCT07121374</a></td><td>PHASE1, PHASE2</td><td>RECRUITING</td><td>37</td><td>NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pl...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05765084" target="_blank">NCT05765084</a></td><td>PHASE1, PHASE2</td><td>RECRUITING</td><td>15</td><td>Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Plat...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04158141" target="_blank">NCT04158141</a></td><td>PHASE3</td><td>TERMINATED</td><td>16</td><td>Phase III Randomized Trial of Pleurectomy/Decortication Plus Systemic Therapy Wi...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01085630" target="_blank">NCT01085630</a></td><td>PHASE2</td><td>COMPLETED</td><td>72</td><td>Randomized Phase II Study of Maintenance Pemetrexed Versus Observation for Patie...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03228537" target="_blank">NCT03228537</a></td><td>PHASE1</td><td>ACTIVE_NOT_RECRUITING</td><td>28</td><td>A Feasibility Trial of Neoadjuvant Cisplatin-Pemetrexed With Atezolizumab in Com...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05932199" target="_blank">NCT05932199</a></td><td>PHASE1, PHASE2</td><td>RECRUITING</td><td>52</td><td>Combination of Induction Durvalumab and Tremelimumab Alone Versus Durvalumab and...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT07234058" target="_blank">NCT07234058</a></td><td>PHASE2</td><td>NOT_YET_RECRUITING</td><td>126</td><td>A NON-COMPARATIVE PHASE IIR TRIAL ASSESSING FIANLIMAB PLUS CEMIPLIMAB PLUS PEMET...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00334594" target="_blank">NCT00334594</a></td><td>PHASE2</td><td>COMPLETED</td><td>153</td><td>Neoadjuvant Chemotherapy and Extrapleural Pneumonectomy of Malignant Pleural Mes...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01105390" target="_blank">NCT01105390</a></td><td>PHASE2</td><td>WITHDRAWN</td><td>0</td><td>A Phase II Trial of AMG 102 in Combination With Pemetrexed and Cisplatin in Pati...</td></tr>
</tbody>
</table>

<h3>相關文獻（20 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/26719230/" target="_blank">26719230</a></td><td>2016</td><td>Article</td><td>Lancet (London, England)</td><td>Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39814199/" target="_blank">39814199</a></td><td>2025</td><td>Article</td><td>Annals of oncology : official </td><td>A randomised phase III study of bevacizumab and carboplatin-pemetrexed chemother...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/26873306/" target="_blank">26873306</a></td><td>2016</td><td>Article</td><td>Therapeutic advances in respir</td><td>Malignant pleural mesothelioma: an update on diagnosis and treatment options.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/25979846/" target="_blank">25979846</a></td><td>2015</td><td>Article</td><td>Cancer treatment reviews</td><td>The established and future biomarkers of malignant pleural mesothelioma.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39818191/" target="_blank">39818191</a></td><td>2025</td><td>Article</td><td>Respiratory investigation</td><td>Current drug therapy for pleural mesothelioma.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/32682189/" target="_blank">32682189</a></td><td>2020</td><td>Article</td><td>Lung cancer (Amsterdam, Nether</td><td>Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30798074/" target="_blank">30798074</a></td><td>2019</td><td>Article</td><td>Annals of diagnostic pathology</td><td>Revisiting localized malignant mesothelioma.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/34750557/" target="_blank">34750557</a></td><td>2021</td><td>Article</td><td>Nature medicine</td><td>Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survi...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30706690/" target="_blank">30706690</a></td><td>2019</td><td>Article</td><td>Thoracic cancer</td><td>Characteristics and long-term outcomes of advanced pleural mesothelioma in Latin...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31569615/" target="_blank">31569615</a></td><td>2019</td><td>Article</td><td>Cancers</td><td>In Vitro Characterization of Cisplatin and Pemetrexed Effects in Malignant Pleur...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39008481/" target="_blank">39008481</a></td><td>2024</td><td>Article</td><td>PloS one</td><td>Integration of the PD-L1 inhibitor atezolizumab and WT1/DC vaccination into stan...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/34491782/" target="_blank">34491782</a></td><td>2022</td><td>Article</td><td>JCO oncology practice</td><td>Management of Advanced Pleural Mesothelioma-At the Crossroads.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31103412/" target="_blank">31103412</a></td><td>2019</td><td>Article</td><td>The Lancet. Respiratory medici</td><td>Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive p...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/33347735/" target="_blank">33347735</a></td><td>2021</td><td>Article</td><td>Diagnostic cytopathology</td><td>Malignant pleural neoplasm with both differentiation of epithelioid mesothelioma...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/40266436/" target="_blank">40266436</a></td><td>2025</td><td>Article</td><td>Current treatment options in o</td><td>Tumor Treating Fields (TTFields) Therapy in Unresectable Pleural Mesothelioma: O...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37572261/" target="_blank">37572261</a></td><td>2023</td><td>Article</td><td>PharmacoEconomics</td><td>Cost Effectiveness and Budget Impact of Nivolumab Plus Ipilimumab Versus Platinu...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/34711664/" target="_blank">34711664</a></td><td>2021</td><td>Article</td><td>Journal for immunotherapy of c</td><td>JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pe...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39624250/" target="_blank">39624250</a></td><td>2024</td><td>Article</td><td>JTO clinical and research repo</td><td>Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/33053560/" target="_blank">33053560</a></td><td>2021</td><td>Article</td><td>Oncology</td><td>Irinotecan and Gemcitabine as Second-Line Treatment in Patients with Malignant P...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31386610/" target="_blank">31386610</a></td><td>2019</td><td>Article</td><td>Journal of clinical oncology :</td><td>Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chem...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. pleural sarcomatoid mesothelioma</span>
<span class="evidence-badge evidence-L2">L2</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content">

<h3>臨床試驗（8 項）</h3>

<table>
<thead>
<tr><th>試驗編號</th><th>階段</th><th>狀態</th><th>人數</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00227630" target="_blank">NCT00227630</a></td><td>PHASE2</td><td>COMPLETED</td><td>59</td><td>A Phase II Feasibility Trial of Induction Chemotherapy Followed by Extrapleural ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01064648" target="_blank">NCT01064648</a></td><td>PHASE1, PHASE2</td><td>ACTIVE_NOT_RECRUITING</td><td>117</td><td>A Phase I/Randomized Phase II Study of Cediranib (NSC#732208) Versus Placebo in ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01085630" target="_blank">NCT01085630</a></td><td>PHASE2</td><td>COMPLETED</td><td>72</td><td>Randomized Phase II Study of Maintenance Pemetrexed Versus Observation for Patie...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00334594" target="_blank">NCT00334594</a></td><td>PHASE2</td><td>COMPLETED</td><td>153</td><td>Neoadjuvant Chemotherapy and Extrapleural Pneumonectomy of Malignant Pleural Mes...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01105390" target="_blank">NCT01105390</a></td><td>PHASE2</td><td>WITHDRAWN</td><td>0</td><td>A Phase II Trial of AMG 102 in Combination With Pemetrexed and Cisplatin in Pati...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02709512" target="_blank">NCT02709512</a></td><td>PHASE2, PHASE3</td><td>COMPLETED</td><td>249</td><td>Randomized, Double-Blind, Phase 2/3 Study in Subjects With Malignant Pleural Mes...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03564691" target="_blank">NCT03564691</a></td><td>PHASE1</td><td>COMPLETED</td><td>470</td><td>A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-4830 as Monotherapy and...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02029690" target="_blank">NCT02029690</a></td><td>PHASE1</td><td>TERMINATED</td><td>85</td><td>Phase 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 Wi...</td></tr>
</tbody>
</table>

<h3>相關文獻（20 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/26719230/" target="_blank">26719230</a></td><td>2016</td><td>Article</td><td>Lancet (London, England)</td><td>Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39818191/" target="_blank">39818191</a></td><td>2025</td><td>Article</td><td>Respiratory investigation</td><td>Current drug therapy for pleural mesothelioma.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30798074/" target="_blank">30798074</a></td><td>2019</td><td>Article</td><td>Annals of diagnostic pathology</td><td>Revisiting localized malignant mesothelioma.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28197626/" target="_blank">28197626</a></td><td>2017</td><td>Article</td><td>International journal of oncol</td><td>Kdm6a and Kdm6b: Altered expression in malignant pleural mesothelioma.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31569615/" target="_blank">31569615</a></td><td>2019</td><td>Article</td><td>Cancers</td><td>In Vitro Characterization of Cisplatin and Pemetrexed Effects in Malignant Pleur...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38204668/" target="_blank">38204668</a></td><td>2023</td><td>Article</td><td>JTCVS open</td><td>Extended pleurectomy/decortication and hyperthermic intraoperative intrapleural ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39624250/" target="_blank">39624250</a></td><td>2024</td><td>Article</td><td>JTO clinical and research repo</td><td>Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31386610/" target="_blank">31386610</a></td><td>2019</td><td>Article</td><td>Journal of clinical oncology :</td><td>Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chem...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/34711664/" target="_blank">34711664</a></td><td>2021</td><td>Article</td><td>Journal for immunotherapy of c</td><td>JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pe...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/35461395/" target="_blank">35461395</a></td><td>2022</td><td>Article</td><td>Virchows Archiv : an internati</td><td>Micro-RNA-215 and -375 regulate thymidylate synthase protein expression in pleur...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/33053560/" target="_blank">33053560</a></td><td>2021</td><td>Article</td><td>Oncology</td><td>Irinotecan and Gemcitabine as Second-Line Treatment in Patients with Malignant P...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/34823894/" target="_blank">34823894</a></td><td>2021</td><td>Article</td><td>Lung cancer (Amsterdam, Nether</td><td>Treatment patterns and outcomes for patients with malignant pleural mesothelioma...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/21651743/" target="_blank">21651743</a></td><td>2012</td><td>Article</td><td>The clinical respiratory journ</td><td>Pemetrexed in malignant pleural mesothelioma and the clinical outcome.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/26538423/" target="_blank">26538423</a></td><td>2015</td><td>Article</td><td>The Lancet. Oncology</td><td>Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mes...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/24507393/" target="_blank">24507393</a></td><td>2013</td><td>Article</td><td>Zhonghua jie he he hu xi za zh</td><td>[Clinicopathological characteristics and prognosis of malignant pleural mesothel...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/24492162/" target="_blank">24492162</a></td><td>2014</td><td>Article</td><td>Clinical lung cancer</td><td>Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive pati...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31455014/" target="_blank">31455014</a></td><td>2019</td><td>Article</td><td>International journal of molec</td><td>Building a Bridge between Chemotherapy and Immunotherapy in Malignant Pleural Me...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/26577445/" target="_blank">26577445</a></td><td>2016</td><td>Article</td><td>International journal of clini</td><td>Trimodality strategy for treating malignant pleural mesothelioma: results of a f...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/34589965/" target="_blank">34589965</a></td><td>2020</td><td>Article</td><td>JTO clinical and research repo</td><td>Expansion Phase 1 Study of Pegargiminase Plus Pemetrexed and Cisplatin in Patien...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/20085865/" target="_blank">20085865</a></td><td>2010</td><td>Article</td><td>Clinical lung cancer</td><td>Carboplatin plus pemetrexed as first-line treatment of patients with malignant p...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. pleural biphasic mesothelioma</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content">

<h3>臨床試驗（5 項）</h3>

<table>
<thead>
<tr><th>試驗編號</th><th>階段</th><th>狀態</th><th>人數</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06155279" target="_blank">NCT06155279</a></td><td>PHASE2</td><td>ACTIVE_NOT_RECRUITING</td><td>41</td><td>Phase II Study of Pembrolizumab in Combination With Cisplatin or Carboplatin and...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04158141" target="_blank">NCT04158141</a></td><td>PHASE3</td><td>TERMINATED</td><td>16</td><td>Phase III Randomized Trial of Pleurectomy/Decortication Plus Systemic Therapy Wi...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03228537" target="_blank">NCT03228537</a></td><td>PHASE1</td><td>ACTIVE_NOT_RECRUITING</td><td>28</td><td>A Feasibility Trial of Neoadjuvant Cisplatin-Pemetrexed With Atezolizumab in Com...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02709512" target="_blank">NCT02709512</a></td><td>PHASE2, PHASE3</td><td>COMPLETED</td><td>249</td><td>Randomized, Double-Blind, Phase 2/3 Study in Subjects With Malignant Pleural Mes...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03564691" target="_blank">NCT03564691</a></td><td>PHASE1</td><td>COMPLETED</td><td>470</td><td>A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-4830 as Monotherapy and...</td></tr>
</tbody>
</table>

<h3>相關文獻（20 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/25979846/" target="_blank">25979846</a></td><td>2015</td><td>Article</td><td>Cancer treatment reviews</td><td>The established and future biomarkers of malignant pleural mesothelioma.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39818191/" target="_blank">39818191</a></td><td>2025</td><td>Article</td><td>Respiratory investigation</td><td>Current drug therapy for pleural mesothelioma.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28197626/" target="_blank">28197626</a></td><td>2017</td><td>Article</td><td>International journal of oncol</td><td>Kdm6a and Kdm6b: Altered expression in malignant pleural mesothelioma.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31569615/" target="_blank">31569615</a></td><td>2019</td><td>Article</td><td>Cancers</td><td>In Vitro Characterization of Cisplatin and Pemetrexed Effects in Malignant Pleur...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39624250/" target="_blank">39624250</a></td><td>2024</td><td>Article</td><td>JTO clinical and research repo</td><td>Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31386610/" target="_blank">31386610</a></td><td>2019</td><td>Article</td><td>Journal of clinical oncology :</td><td>Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chem...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/34711664/" target="_blank">34711664</a></td><td>2021</td><td>Article</td><td>Journal for immunotherapy of c</td><td>JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pe...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/40441085/" target="_blank">40441085</a></td><td>2025</td><td>Article</td><td>Pathology, research and practi</td><td>Cisplatin potentiates PD-L1 expression more robustly than pemetrexed in malignan...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/33053560/" target="_blank">33053560</a></td><td>2021</td><td>Article</td><td>Oncology</td><td>Irinotecan and Gemcitabine as Second-Line Treatment in Patients with Malignant P...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/35461395/" target="_blank">35461395</a></td><td>2022</td><td>Article</td><td>Virchows Archiv : an internati</td><td>Micro-RNA-215 and -375 regulate thymidylate synthase protein expression in pleur...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/34823894/" target="_blank">34823894</a></td><td>2021</td><td>Article</td><td>Lung cancer (Amsterdam, Nether</td><td>Treatment patterns and outcomes for patients with malignant pleural mesothelioma...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/34063225/" target="_blank">34063225</a></td><td>2021</td><td>Article</td><td>Cancers</td><td>Meta-Analysis of Survival and Development of a Prognostic Nomogram for Malignant...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/26715491/" target="_blank">26715491</a></td><td>2015</td><td>Article</td><td>Radiation oncology (London, En</td><td>Long-term results in malignant pleural mesothelioma treated with neoadjuvant che...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28892431/" target="_blank">28892431</a></td><td>2017</td><td>Article</td><td>Journal of clinical oncology :</td><td>Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothel...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/24507393/" target="_blank">24507393</a></td><td>2013</td><td>Article</td><td>Zhonghua jie he he hu xi za zh</td><td>[Clinicopathological characteristics and prognosis of malignant pleural mesothel...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/24989332/" target="_blank">24989332</a></td><td>2014</td><td>Article</td><td>Cancer</td><td>Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetre...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/26577445/" target="_blank">26577445</a></td><td>2016</td><td>Article</td><td>International journal of clini</td><td>Trimodality strategy for treating malignant pleural mesothelioma: results of a f...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/22261805/" target="_blank">22261805</a></td><td>2012</td><td>Article</td><td>Clinical cancer research : an </td><td>CD26 overexpression is associated with prolonged survival and enhanced chemosens...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/34589965/" target="_blank">34589965</a></td><td>2020</td><td>Article</td><td>JTO clinical and research repo</td><td>Expansion Phase 1 Study of Pegargiminase Plus Pemetrexed and Cisplatin in Patien...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/23714495/" target="_blank">23714495</a></td><td>2013</td><td>Article</td><td>American Society of Clinical O</td><td>Peritoneal mesothelioma: the site of origin matters.</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. pericardium cancer</span>
<span class="evidence-badge evidence-L2">L2</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content">

<h3>臨床試驗（3 項）</h3>

<table>
<thead>
<tr><th>試驗編號</th><th>階段</th><th>狀態</th><th>人數</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04462809" target="_blank">NCT04462809</a></td><td>PHASE2</td><td>UNKNOWN</td><td>40</td><td>A Three-Cohort Phase II Trial to Assess the Efficacy of a Maintenance Treatment ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02662504" target="_blank">NCT02662504</a></td><td>PHASE2</td><td>COMPLETED</td><td>6</td><td>Pilot Study of the Feasibility of Intrapleural Photodynamic Therapy in a Multimo...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01590160" target="_blank">NCT01590160</a></td><td>PHASE1, PHASE2</td><td>COMPLETED</td><td>27</td><td>A Phase I/II Study of First Line Ganetespib With Platinum, in Patients With Mali...</td></tr>
</tbody>
</table>

<h3>相關文獻（20 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/17936406/" target="_blank">17936406</a></td><td>2008</td><td>Article</td><td>Lung cancer (Amsterdam, Nether</td><td>Primary pericardial mesothelioma.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/18473795/" target="_blank">18473795</a></td><td>2008</td><td>Article</td><td>Current medicinal chemistry</td><td>Molecular targets and targeted therapies for malignant mesothelioma.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30450660/" target="_blank">30450660</a></td><td>2019</td><td>Article</td><td>Journal of clinical ultrasound</td><td>Localized primary malignant pericardial mesothelioma.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30594459/" target="_blank">30594459</a></td><td>2019</td><td>Article</td><td>Clinical lung cancer</td><td>Treatment and Outcomes of Primary Pericardial Mesothelioma: A Contemporary Revie...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/22104079/" target="_blank">22104079</a></td><td>2012</td><td>Article</td><td>Cancer treatment reviews</td><td>Diffuse malignant peritoneal mesothelioma--an update on treatment.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/32787452/" target="_blank">32787452</a></td><td>2020</td><td>Article</td><td>Journal of investigative medic</td><td>An Unpleasant Surprise: Abdominal Presentation of Malignant Mesothelioma.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39727229/" target="_blank">39727229</a></td><td>2025</td><td>Article</td><td>Thoracic cancer</td><td>EGFR, TP53, and CUL3 Triple Mutation in Non-Small Cell Lung Cancer and its Poten...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/20035722/" target="_blank">20035722</a></td><td>2010</td><td>Article</td><td>Biochemical and biophysical re</td><td>An epigenetic mechanism for capecitabine resistance in mesothelioma.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37248188/" target="_blank">37248188</a></td><td>2023</td><td>Article</td><td>Zhonghua lao dong wei sheng zh</td><td>[A case of malignant peritoneal mesothelioma].</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/15955137/" target="_blank">15955137</a></td><td>2005</td><td>Article</td><td>Respirology (Carlton, Vic.)</td><td>Advances in the diagnosis, evaluation, and management of malignant pleural mesot...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/35117552/" target="_blank">35117552</a></td><td>2020</td><td>Article</td><td>Translational cancer research</td><td>Combined immune checkpoint inhibitor and chemotherapy is effective in a patient ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36602504/" target="_blank">36602504</a></td><td>2022</td><td>Article</td><td>The heart surgery forum</td><td>A Rare Case of Primary Malignant Pericardial Mesothelioma Diagnosed with Pericar...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/26281826/" target="_blank">26281826</a></td><td>2015</td><td>Article</td><td>International journal of radia</td><td>Radical Radiation Therapy After Lung-Sparing Surgery for Malignant Pleural Mesot...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/17762349/" target="_blank">17762349</a></td><td>2007</td><td>Article</td><td>Journal of thoracic oncology :</td><td>Report of a case of pericardial mesothelioma with liver metastases responding we...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/34645482/" target="_blank">34645482</a></td><td>2021</td><td>Article</td><td>Journal of cardiothoracic surg</td><td>Malignant primary pericardial mesothelioma presenting as effusive constrictive p...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/22352060/" target="_blank">22352060</a></td><td>2011</td><td>Article</td><td>Nihon Kokyuki Gakkai zasshi = </td><td>[An autopsied case of primary malignant pericardial mesothelioma diagnosed antem...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/18280176/" target="_blank">18280176</a></td><td>2008</td><td>Article</td><td>European journal of cardio-tho</td><td>Pericardial malignant mesothelioma: a latent complication of radiotherapy?</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/21916183/" target="_blank">21916183</a></td><td>2011</td><td>Article</td><td>Kyobu geka. The Japanese journ</td><td>[Current status of surgical treatment for malignant pleural mesothelioma].</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/24878161/" target="_blank">24878161</a></td><td>2014</td><td>Article</td><td>Revue des maladies respiratoir</td><td>[Intrapericardial lung cancer metastases: Is a curative approach feasible?].</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/17590095/" target="_blank">17590095</a></td><td>2007</td><td>Article</td><td>Anales de medicina interna (Ma</td><td>[Peritoneal mesothelioma: an inusual clinical presentation in a patient without ...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. well differentiated papillary mesothelioma</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content">

<h3>相關文獻（6 篇）</h3>

<table>
<thead>
<tr><th>PMID</th><th>年份</th><th>類型</th><th>期刊</th><th>主要發現</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/23964112/" target="_blank">23964112</a></td><td>2013</td><td>Article</td><td>Japanese journal of clinical o</td><td>Therapeutic strategies for well-differentiated papillary mesothelioma of the per...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28435764/" target="_blank">28435764</a></td><td>2017</td><td>Article</td><td>Cureus</td><td>A Case of Well-Differentiated Papillary Mesothelioma of the Male Peritoneum: Suc...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/23714495/" target="_blank">23714495</a></td><td>2013</td><td>Article</td><td>American Society of Clinical O</td><td>Peritoneal mesothelioma: the site of origin matters.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38806763/" target="_blank">38806763</a></td><td>2024</td><td>Article</td><td>Annals of surgical oncology</td><td>Analysis of Treatment Strategies and Outcomes in Malignant Peritoneal Mesothelio...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/26210689/" target="_blank">26210689</a></td><td>2015</td><td>Article</td><td>Annales de pathologie</td><td>[Peritoneal tumor pathology - case no. 3 : peritoneal well-differentiated papill...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/29147606/" target="_blank">29147606</a></td><td>2017</td><td>Article</td><td>Oncoimmunology</td><td>Temporal and spatial heterogeneity of programmed cell death 1-Ligand 1 expressio...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. lymphohistiocytoid mesothelioma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. iminoglycinuria</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.97%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
</div>

</div>
</details>


## 台灣上市資訊

| 許可證字號 | 商品名 | 適應症 | 狀態 |
|-----------|--------|--------|------|
| 衛部藥陸輸字第000892號 | 培美曲塞二鈉 (原料藥) | 抗腫瘤藥 | 已註銷 |
| 衛部菌疫輸字第001025號 | 吉舒達注射劑 (Keytruda) | 非小細胞肺癌 (與 pemetrexed 併用)、惡性胸膜間皮瘤 (與 pemetrexed 併用) | 有效 |

**注意**：台灣已核准 pembrolizumab 與 pemetrexed 及含鉑化療併用，作為無法切除之晚期或轉移性惡性胸膜間皮瘤的第一線治療。

---

## 安全性考量

### 重要警語

- **骨髓抑制**：嗜中性球低下、血小板低下為劑量限制毒性
- **腎毒性**：需監測腎功能，腎功能不全需調整劑量
- **皮膚毒性**：皮疹常見，可能需要類固醇預防

### 必要補充治療

| 補充劑 | 目的 | 給予方式 |
|--------|------|----------|
| 葉酸 | 減少血液毒性 | 每日口服 350-1000 mcg |
| 維生素 B12 | 減少血液毒性 | 每 9 週肌肉注射 1000 mcg |
| Dexamethasone | 減少皮膚毒性 | 治療前後給予 |

### 藥物交互作用

| 交互作用藥物 | 影響說明 |
|-------------|----------|
| NSAIDs | 可能增加 pemetrexed 毒性，需停藥 |
| 腎毒性藥物 | 增加腎臟損傷風險 |
| 肝素類 | 增加出血風險 |

### 特殊族群

- **腎功能不全 (CrCl < 45 mL/min)**：不建議使用
- **肝功能不全**：輕度可使用，中重度需謹慎
- **孕婦**：禁忌使用
- **老年人**：需密切監測腎功能

---

## 結論與下一步

### 整體評估

Pemetrexed 對惡性間皮瘤 (包括腹膜型) 的預測已獲堅實證據支持：

1. **證據等級最高 (L1)**：多個臨床試驗證實療效
2. **標準治療地位確立**：Pemetrexed + cisplatin 為間皮瘤第一線標準治療
3. **免疫療法組合**：與 PD-1 抑制劑併用已獲台灣核准
4. **適應症延伸**：胸膜和腹膜間皮瘤的治療原則相似

### 目前臨床定位

| 間皮瘤類型 | Pemetrexed 治療角色 |
|-----------|---------------------|
| 惡性胸膜間皮瘤 | 第一線標準治療 (+ cisplatin +/- pembrolizumab) |
| 惡性腹膜間皮瘤 | 第一線化療選項 (+ cisplatin) |

### 建議行動

- **腹膜間皮瘤適應症申請**：若尚未正式核准，可考慮申請適應症擴展
- **臨床經驗累積**：收集實際臨床數據支持療效
- **關注免疫療法組合**：pembrolizumab + pemetrexed 組合可能也適用於腹膜型

---

*本報告由 TxGNN 預測系統生成，僅供研究參考，不構成醫療建議。*


---

## 相關藥物報告

- [Felodipine]({{ "/drugs/felodipine/" | relative_url }}) - 證據等級 L5
- [Iodixanol]({{ "/drugs/iodixanol/" | relative_url }}) - 證據等級 L5
- [Ferrous Gluconate]({{ "/drugs/ferrous_gluconate/" | relative_url }}) - 證據等級 L5
- [Clomipramine]({{ "/drugs/clomipramine/" | relative_url }}) - 證據等級 L5
- [Gefitinib]({{ "/drugs/gefitinib/" | relative_url }}) - 證據等級 L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## 引用本報告

如需引用本報告，請使用以下格式：

**APA 格式：**
```
TwTxGNN. (2026). Pemetrexed老藥新用驗證報告. https://twtxgnn.yao.care/drugs/pemetrexed/
```

**BibTeX 格式：**
```bibtex
@misc{twtxgnn_pemetrexed,
  title = {Pemetrexed老藥新用驗證報告},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/pemetrexed/}
}
```

---

<div class="disclaimer">
<strong>免責聲明</strong><br>
本報告僅供學術研究參考，<strong>不構成醫療建議</strong>。藥物使用請遵循醫師指示，切勿自行調整用藥。任何老藥新用決策需經過完整的臨床驗證與法規審查。
<br><br>
<small>最後審核：2026-02-20 | 審核者：TwTxGNN Research Team</small>
</div>

{% include giscus.html %}
